Patents by Inventor Christopher Patrick Marshall
Christopher Patrick Marshall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11922504Abstract: An asset management system is disclosed where a plurality of financial databases may connect with and be in communication with an asset management tool. The asset management tool is able to create an individual spending plan (scheduled distributions) and matching fixed income investment portfolio for a user based on inputted parameters with automatic distributions from the portfolio consistent with the individual spending plan occurring with a high degree of certainty. The asset management tool may communicate with the plurality of financial databases to put the individual spending plan and matching portfolio into action and is able to calculate and communicate an optimized surplus investment as a means of self-insuring so that the predefined schedule of distributions is met with the effective certainty one would expect from an insured/guaranteed income product.Type: GrantFiled: October 19, 2021Date of Patent: March 5, 2024Assignee: NISA Investment Advisors, LLCInventors: William Patrick Marshall, Christopher Eric Goebel, Nicholas Frank Cangiani
-
Patent number: 11752191Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.Type: GrantFiled: November 30, 2020Date of Patent: September 12, 2023Inventor: Christopher Patrick Marshall
-
Publication number: 20220288189Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: ApplicationFiled: September 27, 2021Publication date: September 15, 2022Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Publication number: 20220119454Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.Type: ApplicationFiled: May 27, 2021Publication date: April 21, 2022Applicants: CALDER BIOSCIENCES INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICInventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
-
Publication number: 20210322512Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.Type: ApplicationFiled: November 30, 2020Publication date: October 21, 2021Inventor: Christopher Patrick Marshall
-
Patent number: 11129887Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: GrantFiled: December 22, 2017Date of Patent: September 28, 2021Assignee: Calder Biosciences Inc.Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Publication number: 20190292228Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.Type: ApplicationFiled: October 9, 2018Publication date: September 26, 2019Applicants: CALDER BIOSCIENCES INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HELATHInventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
-
Publication number: 20190105368Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.Type: ApplicationFiled: December 8, 2018Publication date: April 11, 2019Inventor: Christopher Patrick Marshall
-
Patent number: 10155023Abstract: The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.Type: GrantFiled: February 3, 2017Date of Patent: December 18, 2018Assignee: CALDER BIOSCIENCES INC.Inventor: Christopher Patrick Marshall
-
Patent number: 10125172Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.Type: GrantFiled: July 24, 2014Date of Patent: November 13, 2018Assignees: CALDER BIOSCIENCES INC., THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani
-
Publication number: 20180243403Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: ApplicationFiled: December 22, 2017Publication date: August 30, 2018Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Publication number: 20170072045Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: ApplicationFiled: June 15, 2016Publication date: March 16, 2017Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Patent number: 9393297Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: GrantFiled: August 2, 2014Date of Patent: July 19, 2016Assignee: AVATAR MEDICAL, LLCInventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Publication number: 20150056233Abstract: In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens.Type: ApplicationFiled: August 2, 2014Publication date: February 26, 2015Inventors: Christopher Patrick Marshall, Peter Joseph Alff, Claudio Bertuccioli, Mark Andrew Yondola
-
Publication number: 20150030622Abstract: In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same.Type: ApplicationFiled: July 24, 2014Publication date: January 29, 2015Inventors: Christopher Patrick Marshall, Jason Scott McLellan, Peter Joseph Alff, Claudio Bertuccioli, Roberto Mariani